Reviva Pharmaceuticals Holdings Stock Beta
| RVPH Stock | USD 1.24 0.10 8.77% |
Reviva Pharmaceuticals Holdings fundamentals help investors to digest information that contributes to Reviva Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Reviva Stock. The fundamental analysis module provides a way to measure Reviva Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Reviva Pharmaceuticals stock.
Reviva | Beta |
Reviva Pharmaceuticals Holdings Company Beta Analysis
Reviva Pharmaceuticals' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Reviva Pharmaceuticals Beta | -0.055 |
Most of Reviva Pharmaceuticals' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Reviva Pharmaceuticals Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Reviva Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Reviva Pharmaceuticals is extremely important. It helps to project a fair market value of Reviva Stock properly, considering its historical fundamentals such as Beta. Since Reviva Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Reviva Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Reviva Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Reviva Pharmaceuticals Holdings has a Beta of -0.055. This is 106.4% lower than that of the Biotechnology sector and 103.96% lower than that of the Health Care industry. The beta for all United States stocks is 63.33% lower than that of the firm.
Reviva Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Reviva Pharmaceuticals' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Reviva Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reviva Pharmaceuticals by comparing valuation metrics of similar companies.Reviva Pharmaceuticals is currently under evaluation in beta category among its peers.
Reviva Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Reviva Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Reviva Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Reviva Pharmaceuticals' value.| Shares | Blackrock Inc | 2024-06-30 | 102.9 K | State Street Corp | 2024-06-30 | 71.4 K | Northern Trust Corp | 2024-09-30 | 57.7 K | Susquehanna International Group, Llp | 2024-06-30 | 41 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 35.9 K | Sound Income Strategies | 2024-09-30 | 30 K | Group One Trading, Lp | 2024-06-30 | 29.4 K | Two Sigma Investments Llc | 2024-09-30 | 21.4 K | Emc Capital Management(tx) | 2024-09-30 | 18.4 K | Armistice Capital, Llc | 2024-09-30 | 3.2 M | Woodline Partners Lp | 2024-06-30 | 1.6 M |
As returns on the market increase, returns on owning Reviva Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Reviva Pharmaceuticals is likely to outperform the market.
Reviva Fundamentals
| Return On Equity | -17.95 | ||||
| Return On Asset | -2.34 | ||||
| Current Valuation | 32.65 M | ||||
| Shares Outstanding | 33.44 M | ||||
| Shares Owned By Insiders | 14.78 % | ||||
| Shares Owned By Institutions | 30.06 % | ||||
| Number Of Shares Shorted | 6.43 M | ||||
| Price To Book | 8.35 X | ||||
| EBITDA | (39.5 T) | ||||
| Net Income | (39.26 M) | ||||
| Cash And Equivalents | 23.19 M | ||||
| Cash Per Share | 1.13 X | ||||
| Total Debt | 17.98 M | ||||
| Current Ratio | 6.72 X | ||||
| Book Value Per Share | 0.20 X | ||||
| Cash Flow From Operations | (28.32 M) | ||||
| Short Ratio | 19.04 X | ||||
| Earnings Per Share | (1.08) X | ||||
| Target Price | 15.2 | ||||
| Number Of Employees | 15 | ||||
| Beta | -0.055 | ||||
| Market Capitalization | 38.12 M | ||||
| Total Asset | 23.7 M | ||||
| Retained Earnings | (134.35 M) | ||||
| Working Capital | 6.53 M | ||||
| Net Asset | 23.7 M |
About Reviva Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Reviva Pharmaceuticals Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reviva Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reviva Pharmaceuticals Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Reviva Pharmaceuticals is a strong investment it is important to analyze Reviva Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reviva Pharmaceuticals' future performance. For an informed investment choice regarding Reviva Stock, refer to the following important reports:Check out Reviva Pharmaceuticals Piotroski F Score and Reviva Pharmaceuticals Altman Z Score analysis. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Return On Assets (2.34) | Return On Equity (17.95) |
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.